CassandraBio
Pipeline dossier

NIH & clinical-trial pipeline signals for BRISTOL MYERS SQUIBB CO (BMY)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for BMY, mapped to public ticker BMY (CIK 0000014272). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →
Trial → FilingBMY55% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE2 primary completion in ~44 days

Upstream (observed)
Clinical trial status (PHASE2) — Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)
trial ↗filings ↗
Trial → FilingBMY35% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)
trial ↗filings ↗
Trial → FilingBMY35% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE3 protocol updated 7 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)
trial ↗filings ↗

Recent SEC 8-K filings

JSON API for this entity →